دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Keep it Simple: A Proposal for a New Definition of Uncomplicated and Complicated Urinary Tract Infections from the EAU Urological Infections Guidelines Panel
Gernot Bonkat a b, Florian Wagenlehner b c, Jennifer Kranz b d e
Rethinking Stone-free Rates and Surgical Outcomes in Endourology: A Point of View from PEARLS Members
Frédéric Panthier a b c d, Vineet Gauhar b e, Eugenio Ventimiglia b f g, Jia-Lun Kwok b h, Etienne Xavier Keller b f i, Olivier Traxer a b c
Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review
Adam B. Weiner a b, Preeti Kakani a, Andrew J. Armstrong c, Alberto Bossi d, Philip Cornford e, Felix Feng f, Pratik Kanabur a, R. Jeffery Karnes g, Rana R. Mckay h, Todd M. Morgan i, Edward M. Schaeffer j, Neal Shore k, Alison C. Tree l, Daniel E. Spratt m
All Biochemical Recurrences Are Equal, but Some Are More Equal than Others
Verane Achard a b, Bertrand Tombal c
Summary Paper on Underactive Bladder from the European Association of Urology Guidelines on Non-neurogenic Male Lower Urinary Tract Symptoms
Michael Baboudjian a b c d, Hashim Hashim e, Nikita Bhatt f, Massimiliano Creta g, Cosimo De Nunzio h, Mauro Gacci i j, Thomas Herrmann k, Markos Karavitakis l, Sachin Malde m, Lisa Moris n o, Christopher Netsch p, Malte Rieken q, Vasileios Sakalis r, Natasha Schouten s, Manuela Tutolo t, Jean-Nicolas Cornu u
Underactive Bladder According to the European Association of Urology Guidelines
Michael Chancellor *
Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial
Andreas Josefsson a b c, Marianne Månsson a, Kimia Kohestani a, Vasiliki Spyratou a, Jonas Wallström d, Mikael Hellström d e, Hans Lilja f g h i, Andrew Vickers j, Sigrid V. Carlsson a g j k, Rebecka Godtman a, Jonas Hugosson a
Biomarkers in Prostate Cancer Screening: Sometimes “More is More�
Arnav Srivastava, Patrick Lewicki, Todd M. Morgan
Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment?
Michael Baboudjian a b c, Romain Diamand d, Alessandro Uleri e, Jean-Baptiste Beauval a, Alae Touzani a, Jean-Baptiste Roche f, Vito Lacetera g, Thierry Roumeguère d, Giuseppe Simone h, Daniel Benamran i, Alexandre Fourcade j, Bastien Gondran-Tellier b, Gaelle Fiard k, Alexandre Peltier d, Guillaume Ploussard a
Reducing or Increasing Overtreatment? How Do We Measure the Impact of Magnetic Resonance Imaging–targeted Biopsy on Prostate Cancer Mortality?
Samir S. Taneja *
PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer
Cameron Englman a b †, Davide Maffei a c d †, Clare Allen b, Alex Kirkham b, Peter Albertsen e, Veeru Kasivisvanathan a d, Ronaldo Hueb Baroni f, Alberto Briganti g h, Pieter De Visschere i, Louise Dickinson a b, Juan Gómez Rivas j, Masoom A. Haider k, Claudia Kesch l, Stacy Loeb m, Katarzyna J. Macura n, Daniel Margolis o, Anita M. Mitra p, Anwar R. Padhani q, Valeria Panebianco r, Peter A. Pinto s…Caroline M. Moore a d ‡
PRECISE v2: An Enhanced Framework To Guide Future Research on the Use of Magnetic Resonance Imaging in Prostate Cancer Active Surveillance
Matthew R. Cooperberg *
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial
Primo N. Lara Jr a, Catherine Tangen b, Elisabeth I. Heath c, Shuchi Gulati a, Mark N. Stein d, Maxwell Meng e, Ajjai Shivaram Alva f, Sumanta K. Pal g, Igor Puzanov h, Joseph I. Clark i, Toni K. Choueiri j, Neeraj Agarwal k, Robert Uzzo l, Naomi B. Haas m, Timothy W. Synold g, Melissa Plets b, Ulka N. Vaishampayan f, Brian M. Shuch n, Seth Lerner o, Ian M. Thompson Jr p…Christopher W. Ryan q
EVEREST: Attempting the Summit with Adjuvant Everolimus To Treat High-risk Renal Cell Carcinoma After Surgery
Jens Bedke a, Axel Bex b c d
Whole-body Diffusion-weighted Magnetic Resonance Imaging for Assessment of the Bone Response Rate in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Enzalutamide
Alberto Dalla Volta a, Francesca Valcamonico a, Andrea Zivi b c, Giuseppe Procopio d, Pierangela Sepe d, Gianluca Del Conte e, Nunzia Di Meo f, Silvia Foti e, Stefania Zamboni g, Caterina Messina h, Eleonora Lucchini i, Anna Rizzi j, Marco Ravanelli f, Stefano Calza k, Francesca Zacchi b c, Giovannino Ciccone l, Nazareno Suardi g, Roberto Maroldi f, Davide Farina f, Alfredo Berruti a
Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial
Alonso Garcia-Ruiz a, Carlos Macarro a, Francesca Zacchi a b c, Rafael Morales-Barrera a b, Francesco Grussu a, Irene Casanova-Salas a, Francesco Sanguedolce d e, Macarena Gonzalez a b, Pablo Cresta-Morgado a b, Matias de Albert b, Josep Garcia-Bennett f, David Marmolejo a b, Jacques Planas b, Sarai Roche b, Richard Mast b, Christina Zatse a, Josep M Piulats f g, Bernardo Herrera-Imbroda h, Lucas Regis b, Laura Agundez a…Raquel Perez-Lopez a
High-performing, Accessible, and Affordable Imaging in Metastatic Prostate Cancer: Is Whole-body Magnetic Resonance Imaging the Answer?
Sola Adeleke *
Re: Assessment of Artificial Intelligence Chatbot Responses to Top Searched Queries About Cancer
Francesco Cei a b c d, Giovanni Enrico Cacciamani a b c
Re: Erdafitinib in BCG-treated High-risk Non-muscle-invasive Bladder Cancer
Marko Babjuk a b
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
Niklas Klümper a b, Francisco E. Vera-Badillo c, Markus Eckstein d e, Boris Hadaschik f, Viktor Grünwald f g
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
David C. Chen a, Haidar AlSaffar a, Henrike Graefen a b, Sachin Perera a, Elio Mazzone a, Marlon L. Perera a c, Nathan Lawrentschuk a d e, Declan G. Murphy a e
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
Martina Catalano a, Matteo Santoni b, Giandomenico Roviello a
Re: First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma
Alice Thomson a, Carlotta Castillo a b, Henrike Graefen a c, Sachin Perera a, Nathan Lawrentschuk a d, Marlon Perera a, Renu Eapen a, Declan G. Murphy a e
Decision Regret Regarding Treatment Choices 1 Year After a New Diagnosis of Bladder Cancer
Kate Absolom a, Zoe Rogers a, James W.F. Catto b c, Sarah Bottomley b, Adam Glaser d e, Amy Downing a f, Life and Bladder Cancer Study Group
Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging–visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003
Hein V. Stroomberg a b, Klaus Brasso a c, Andreas Røder a c
Reply to Hein V. Stroomberg, Klaus Brasso, and Andreas Røder’s Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging–visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003
Alessandro Uleri a, Michael Baboudjian a b, Romain Diamand c, Guillaume Ploussard b
Re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.016
Anwar R. Padhani a, Frederic Lecouvet b, Giuseppe Petralia c, Dow-Mu Koh d
Reply to Anwar R. Padhani, Frederic LeCouvet, Giuseppe Petralia, and Dow-Mu Koh’s Letter to the Editor re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.016
Alonso Garcia-Ruiz a, Carlos Macarro a, Joaquin Mateo a b, Raquel Perez-Lopez a
Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging–visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003
Andrew J. Vickers *
Reply to Andrew J. Vickers’ Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging–visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003
Alessandro Uleri a, Michael Baboudjian a b, Romain Diamand c, Guillaume Ploussard b
Re: Roxana Ramos, Ethan Ferguson, Mahmoud Abou Zeinab, et al. Single-port Transvesical Robot-assisted Simple Prostatectomy: Surgical Technique and Clinical Outcomes. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.11.012
Jas Singh
Corrigendum to “Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial� [Eur. Eurol. 84(2) (2023) 156–163]
Oliver Sartor a, Theodore G. Karrison b, Howard M. Sandler c, Leonard G. Gomella d, Mahul Amin c, James Purdy e, Jeff M. Michalski f, Mark G. Garzotto g, Nadeem Pervez h, Alexander G. Balogh i, George B. Rodrigues j, Luis Souhami k, M. Neil Reaume l, Scott G. Williams m, Raquibul Hannan n, Christopher U. Jones o, Eric M. Horwitz p, Joseph P. Rodgers b, Felix Y. Feng q, Seth A. Rosenthal o
